Blockchain Registration Transaction Record

NanoViricides Raises $2M to Advance Broad-Spectrum Antiviral NV-387

NanoViricides closes $2M offering to fund NV-387, a broad-spectrum antiviral targeting COVID-19, RSV, and influenza. Learn about the company's pipeline and technology.

This funding matters because it supports NanoViricides' development of NV-387, a potential broad-spectrum antiviral that could address multiple viral threats including COVID-19, RSV, and influenza. If successful, it could provide a versatile tool against current and future pandemics, reducing reliance on virus-specific treatments. The company's approach using nanoviricide technology may offer novel mechanisms to combat antiviral resistance, impacting global health preparedness.